



(51) International Patent Classification:

A61K 31/4164 (2006.01) C07D 233/60 (2006.01)
C07D 233/06 (2006.01) C07D 401/14 (2006.01)
C07D 249/16 (2006.01) A61P 25/16 (2006.01)
A61K 31/4184 (2006.01) C07D 233/61 (2006.01)
C07D 233/58 (2006.01) A61P 25/18 (2006.01)
C07D 401/04 (2006.01) C07D 235/20 (2006.01)
A61K 31/4196 (2006.01)

(21) International Application Number:

PCT/SG2009/000112

(22) International Filing Date:

31 March 2009 (31.03.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/064,870 31 March 2008 (31.03.2008) US

(71) Applicant (for all designated States except US): **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Con-nexis, Singapore 138632 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHUO, Lang** [US/SG]; Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos #04-01, Singapore 138669 (SG). **HO, Gideon** [SG/SG]; Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos #04-01, Singapore 138669 (SG). **ZHANG, YU-GEN** [CN/SG]; Institute of Bioengineering and Nanotechnology, 31 Biopolis way, #04-01 Nanos, Singapore 138669 (SG). **YING, Jackie, Y.** [US/SG]; Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #04-01 Nanos, Singapore 138669 (SG).

(74) Agent: **YU SARN AUDREY & PARTNERS**; 17 Upper Circular Road, #03-00, Jura Building, Singapore 058415 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS




FIGURE 4

(57) Abstract: There is presently provided methods for delivering a neuroprotective agent to a neural cell. The methods comprise contacting a neural cell with an imidazolium or imidazolinium compound as described herein, including an imidazolium or imidazolinium salt.